Tuesday, 30 April 2019

Lactose Intolerance Treatment Market to Observe Significant Growth by 2019

According to the analysis offered by Market Research Future (MRFR), the global lactose intolerance treatment market is on track to witness growth at a CAGR of 7.2% during the assessment period from 2017 to 2023 which will result in a market value of USD 9.8 Bn by the end of the review period.
Lactose intolerance is caused by a deficiency of lactase enzymes in the body, and the issue is often accompanied by undesirable symptoms such as abdominal cramps, bloating, diarrhea, gas, and others. Lactose is a sugar which is commonly available in dairy; lactose intolerant consumers often have to resort to treatments to manage lactose intolerance. The condition is incurable and can only be managed. As a result, the lactose intolerance treatment market is likely to witness significant growth as patients need ongoing treatment. Market Research Future's meticulous study on the global lactose intolerance treatment market includes several crucial market findings including growth rate and market values.
Lactose intolerance can be caused by a natural reduction in lactase production in the body, or as a side effect of other gastrointestinal conditions. The condition can also be hereditary. Several F&B companies have been tapping into the treatment market by creating dairy-free alternatives. These companies cater to both vegan consumer bases and lactose intolerance consumer bases. The nutritional value associated with consumption of dairy substitutes and the growing demand for the same as lactose intolerance prevails has resulted in the launch of several creative non-dairy products. Ranging from non-dairy cheese to non-dairy yogurt and milk, lactose intolerant consumers have many options with which to treat lactose intolerance. The increasing affordability of lactose-free food and increasing sales are expected to provide the market with a considerable boost.
Symptoms of lactose intolerance are non-serious and are often viewed as an inconvenience. As a result, many people simply ignore the symptoms, thus restraining market growth. Rising awareness regarding lactose intolerance and an increasing focus on health is expected to mitigate this to some extent and result in opportunities for growth.
Key Players
Profiles and growth strategies of leading market participants have been included in MRFR’s competitive analysis. Market players include Scimera Partners, Parmalat, National Enzyme Company, Vetbiochem India Private Limited, Arla Foods, Valio, Daiya Foods Inc., Oberland-Milchverwertung (OMIRA), Johnson & Johnson Inc., McNeil Nutritionals, Ganeden Biotech and others.
Market Segmentation
The lactose intolerance treatment market is segmented on the basis of treatment, type, region and end users. On the basis of type, the lactose intolerance treatment market has been segmented into secondary, primary, developmental and congenital. The treatment basis of segmentation of the market has been segmented into food supplements such as milk substitutes (soy, coconut, rice, almond among others), cereals and breads, dairy, fats, and others, enzymatic lactase supplements, and others. The end user segment of the market comprises of home use, hospitals and clinics, and others. The regions that are a share of the global lactose intolerance treatment market are the Middle East, Africa, Europe, North America, and the Asia Pacific.
Latest Industry News
  • Start-up Perfect Day is collaborating with Archer Daniels Midland to crease lactose-free whey which is plant-based.
Regional Analysis
The regional analysis of the lactose treatment market includes regions such as the Middle East, Africa, Europe, North America and the Asia Pacific. In the North American region, the US is responsible for the greatest market portion owing to the promising reimbursement scenario and better spending on healthcare. The quicker market acceptance of new technology in the US is also a vital driver of the market for lactose intolerance treatment. The European region is the following major market owing to the incidence of large disposable income and increasing awareness. Asia Pacific region is likely to have the most capability and it is projected to be run by countries such as China and India. The Middle East & African market is directed by the Gulf nations mainly by countries such as Saudi Arabia and UAE. The underprivileged regions of the Africa region are anticipated to be growing at a slow rate due to lowly economic and political conditions and pitiable healthcare penetration.
Browse Complete 90 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/lactose-intolerance-treatment-market-3868
         
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Esophageal Cancer Market in depth study and analysis published, 2019

Esophageal is the tube like structure that connects mouth to stomach and help to get foods and liquid. Esophageal cancer develop uncontrolled cancerous cells anywhere along the esophagus. Esophageal cancer consider as a sixth most common cause of cancer deaths around the globe. The disease is characterized by disordered and deregulated cellular and stromal explosion along with reduced cell death and growth factor deprivation, and such other factors. The two main sub-types of esophageal cancer are esophageal squamous-cell carcinoma which arises from the epithelial cells and esophageal adenocarcinoma which arises from the glandular cells. According to the American Cancer Society in 2017 the esophageal cancer rate in the United States was about 16,940 cases diagnosed resulting in 15,690 deaths. The disease is also 3 to 4 times more common among men than women.
The global esophageal cancer market is showing the steady growth; mainly owing to increase in patient population. Also, the chances of develop esophageal cancer increases with age and the occurrence of esophageal cancer are much low in children and young adults in comparison to people over 55 year. According to report published by Cancer Research UK, in 2014, it is estimated that around 8,919 incidence of esophageal cancer found in the United Kingdom. These rising number of esophageal cancer create an opportunity for the player to introduce innovative treatment option.
Considering all these factors the market for esophageal cancer is expected to reach $ 1000.1 million by the end of 2023, this market is projected to growing at a CAGR of ~ 8.7 % during 2017-2023.
Key players of Global Esophageal cancer Market:
  • Amgen
  • Eli Lilly and Company,
  • Hoffmann-La Roche,
  • Bristol-Myers Squibb Company,
  • Boehringer Ingelheim GmbH,
  • Bristol-Myers Squibb,
  • GlaxoSmithKline Plc.,
  • Novartis AG,
  • Johnson & Johnson,
  • Gilead Sciences,
  • Merck & Co.
Segmentation:
The global esophageal cancer market is segmented on the basis of type. Based on the type, the market has been segmented as esophageal squamous-cell carcinoma, esophageal adenocarcinoma and others. Based on the phases, the market has been segmented as phase I, phases II and phases III. Based on the treatment, the market has been segmented as surgery, chemotherapy and radiotherapy and other.
Intended Audience
  • Global Esophageal cancer solutions providers, manufacturers & suppliers
  • Research and development (R&D) companies
  • Market research and consulting service providers
  • Academic institutes and universities
Regional Analysis
US accounts for the maximum market share due to favorable reimbursement scenario and greater expenditure on healthcare. Europe is the second largest market due to large disposable income and rising awareness. Asia pacific region will be the fastest region because of large unmet needs which will be led by China and India. The Middle East and Africa market will be led by the gulf nations particularly Saudi Arabia and UAE. The poor regions of Africa is expected to be a laggard due to poor economic and political conditions.
Browse Complete 110 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/esophageal-cancer-market-3280


About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Monday, 29 April 2019

Cowden Syndrome Market, Segments, Growth and Value Chain 2019

Cowden syndrome is part of the PTEN hamartoma tumor syndrome. Cowden syndrome is characterized by a high risk of both benign and cancerous tumors of the breast, thyroid, endometrium, colorectal, kidney, and skin. The global Cowden syndrome market is expecting a healthy growth in the coming future. The global market is majorly driven by increasing Cowden syndrome patients across the globe. Additionally, increasing smoking population and rising consumption of alcohol have spurred the growth of the market. However, long time for approval and side effects of the treatment may hinder the growth of the market.
The global Cowden syndrome market is expected to grow at a CAGR of 6.7% during the forecast period 2017-2023.
Key Players
Some of key the players in the market are Amgen, Inc. (U.S.), Eli Lilly and Company (U.S.), AstraZeneca Plc. (U.K.), Bristol-Myers Squibb Company (U.S.), Sanofi (France), AbbVie Inc. (U.S.), Spectrum Pharmaceuticals Inc. (U.S.), Novartis AG (Switzerland), GlaxoSmithKline Plc. (U.K.), Bayer AG (Germany), Takeda Pharmaceuticals (Japan), Pfizer, Inc. (U.S.), Merck & Co., Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Janssen Biotech, Inc. (U.S.), Immunomedics (U.S.), and Oncomed Pharmaceuticals (U.S.)
Segmentation
The global Cowden syndrome market is segmented on the basis of site, treatment and end users.
On the basis of the site, the market is segmented into the breast, thyroid, endometrium (uterus), colorectal, kidney, skin (melanoma), and others.
On the basis of the treatment, the market is categorized into genetic testing, chemotherapy, surgery & radiation therapy, targeted therapy, hormone therapy, biologic therapy, and other. The chemotherapy is further segmented into anthracyclines, taxanes, antimetabolites, and alkylating agents. The targeted therapy is sub-segmented with monoclonal antibodies and tyrosine kinase inhibitors. Hormone therapy is further segmented into selective estrogen-receptor modulators (SERMs), aromatase inhibitors, and others.
On the basis of end users, the market is segmented into hospital & clinics, ambulatory care centers, and others.
Regional Analysis
The Americas dominate the global Cowden syndrome market owing to the increasing prevalence of people suffering from Cowden syndrome and cancer. Additionally, high healthcare expenditure, well-developed technology, and strong government support for research & development have fuelled the growth of the Americas Cowden syndrome market. Presence of the leading players and increasing availability of funds in this region are likely to support the growth in the coming future.
On the other hand, the Middle East & Africa hold the least share of the market due to limited availability of funds and availability of medical facilities, and poor political conditions in Africa. The Middle East holds the major share in the Middle East & Africa Cowden syndrome market. Kuwait, Qatar, Oman, and South Arabia holds the major share of the Middle East market. However, the African region is expecting a healthy growth due to the presence of a huge opportunity for the development of the market.
And The Europe accounts for the second largest Cowden syndrome market, which is followed by the Asia Pacific. Availability of the funds for research & development and strong government support have driven the market growth. The Asia Pacific is the fastest growing Cowden syndrome market owing to the increasing prevalence of cancer, rapidly developing the economy and increasing government support. India and China are expected to lead the market in this region.
Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/cowden-syndrome-market-5096


About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Mortuary Refrigerator Market to show steady growth, 2019

Mortuary Refrigerator Market Scenario:
Mortuary refrigerators are the largely used equipment in the whole mortuary equipment market. These refrigerators have available with several features such as temperature adjustable knob, multiple chambers. Mortuary refrigerators are available in both positive and negative temperature facility. The positive temperature refrigerator slows down the degradation process of dead bodies for a period of time, and the negative temperature mortuary refrigerators are used to storage the body by freezing it and prevent degradation for longer duration. The increase in technology and rising demand for automation in mortuary procedures is one of the reasons for the larger share of the market.
The global mortuary refrigerator market is expected to register a CAGR of 4.3% during the forecast period of 2018 to 2023.
Mortuary refrigerators are used to keep dead bodies as a solution to maintain hygiene requirements in hospitals. The key factors contributing for the market growth are growing number of cancer patient and cancer-related research, increasing organ transplant, and growing demands for automation in mortuary procedures. Also, the increasing geriatric population, is contributing to drive the market. According to the United Census Bureau, the global-female-geriatric population is estimated to reach 4,139 million by 2030 from 3,601 million in 2015. However, the minimal awareness about mortuary equipment and fluctuating prices of raw materials and substituting products for mortuary refrigerators hinders the market growth.
There are several companies involved in manufacturing of mortuary refrigerators with advanced features and ease to use. However, the cost of mortuary refrigerators compare to other mortuary related products and presence of alternative products in the market are hindering the market growth.
Global Key Players
  • LEEC
  • Hygeco
  • Paragon scare Ltd.
  • Thalheimer Kühlung
  • Barber Medical
  • CEABIS
  • EIHF Isofroid
  • EVERmed
  • Fiocchetti and Funeralia
Segmentation
The global mortuary refrigerator market is segmented on the basis of product type, application, application, end user, and region.
On the basis of product type, the market is segmented into positive temperature, negative temperature refrigerators.
By application, the market is categorised into corpses storage and forensic investigation. On the basis of end-user, the global mortuary refrigerator market is categorised into forensic labs, research and academics, funeral homes, hospitals and clinics, and others.
Regional Market Summary
The Americas dominates the global market for mortuary refrigerator owing to the increase in cancer and cancer-related research activities, increasing number of geriatric populations with health-related problems and presence of major market players within the region boosts the market growth. According to the Administration for Community Living in 2016, the number of older women within the region was estimated to be 26.7 million. Furthermore, the presence of developed economies and regulations by various authorities in healthcare sector within the region boosts the market growth.
In 2017, it was estimated that Europe stood second in the global mortuary refrigerator market. The increase in demand for mortuary refrigerator by forensic labs and hospitals to store the dead bodies for investigation increases the market growth. These equipment’s are also, used to store the entire body donated for medical research purpose, which are used in medical colleges to teach human anatomy.
Asia Pacific was the fastest growing region for the global mortuary refrigerator market in 2017. Factors such as increasing awareness about the advanced and innovative mortuary refrigerator, growing regulations and policies by various authorities regarding the hygiene in hospital drives the market growth.
On the other hand, the Middle East and Africa holds a least share in the global mortuary refrigerator market due to the lack of awareness about the advanced mortuary procedures and mortuary refrigerator hinders the market growth in this region.
Browse Complete 110 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/mortuary-refrigerator-market-7437
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Male Breast Cancer Market, Segments, Growth and Value Chain 2019

Although breast cancer is common in women, even men suffer from the same. Men also have breast tissues and cancer starts when these tissues start to grow out of control. The breast ducts and glands present in men are not functional, but cancer in these areas can spread when cancer cells enter the blood or lymph system and are carried in the whole body. Men who have suffered from cancer before and undergone radiation therapy are at a high risk of suffering from male breast cancer. The rising geriatric population and an increasingly obese population resulting in high levels of estrogen in males are expected to drive the growth of the market during the forecast period. According to an article published by the National Cancer Institute in April 2018, most of the men who suffer from breast cancer are 60 to 70 years old. Additionally, the rising healthcare expenditure is likely to boost the market growth. On the other hand, lack of knowledge of the disease and high cost of treatment may hinder the growth of the market during the forecast period.
Numerous factors such as increasing obese population and growing geriatric population are expected to drive the growth of the market. For instance, in July 2017, the Bristol-Myers Squibb Company announced a broad clinical collaboration with Clovis Oncology for evaluating the combination of cancer drugs Nivolumab and Rucaparib in Phase 2 and Phase 3 clinical trials in multiple tumor types.
Moreover, favorable healthcare expenditures boost the growth of the market. However, lack of knowledge and the high cost of treatments may hamper the market growth during the assessment period.
The global male breast cancer market is expected to grow slowly at a CAGR of ~ 3.6% during the forecast period from 2018 to 2023. Male breast cancer is caused when the breast tissues of males start growing out of control and become cancerous.
Key players
Achieve Life Sciences, Inc., Pfizer, Eli Lilly and Company, Bristol-Myers Squibb Company, F. Hoffmann-La Roche, Sanofi, Novartis AG, BioNumerik Pharmaceuticals Inc., Seattle Genetics, Inc., GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., AstraZeneca, Accord Healthcare, and Bayer AG are some of the key players in the global male breast cancer market.
Segmentation
The global male breast cancer market has been segmented into type, diagnosis, and treatment.
The market, on the basis of type, has been segmented into, ductal carcinoma in situ, Paget’s disease of the nipple, inflammatory breast cancer, and infiltrating ductal carcinoma.
The market, by diagnosis, has been segmented into, mammography, biopsy, PET scan, CT scan, MRI scan, and other tests. On the basis of diagnosis, biopsy is anticipated to record the largest growth owing to its accuracy of diagnosing the disease. It is also expected to be the fastest growing segment.
By diagnosis, biopsy is further segmented into, fine needle aspiration biopsy, core biopsy, and excisional biopsy.
The market, by treatment, has been segmented into, local treatments and systemic treatments.
By treatment, local treatments are further segment into, surgery and radiation therapy.
Surgery is further segmented into, mastectomy, breast-conserving surgery, and lymph nodes biopsy.
By treatment, systemic treatments are further segmented into, chemotherapy, hormone therapy, and targeted therapy.
Hormone therapy is further segmented into, using drugs and orchiectomy (castration).
Chemotherapy is further segmented into, adjuvant therapy and neoadjuvant therapy.
Targeted therapy is further segmented into, for HER2 positive breast cancer, for hormone receptor-positive breast cancer, and for cancer with BRCA mutations.
The European male breast cancer market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The male breast cancer market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The male breast cancer market in the Middle East and Africa has been segmented into the Middle East and Africa.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The male breast cancer market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
Regional Market Summary
Geographically, the Americas is anticipated to dominate the global male breast cancer market owing to the changing lifestyle and rising prevalence of breast cancer. According to an article published by, the American Cancer Society in April 2018, the lifetime risk of getting breast cancer in men is approximately 1 in 833. Europe is expected to hold the second largest position in the global male breast cancer market. The market growth in this region is attributed to the growing prevalence of rare cancers, the availability of funds for research, and increasing healthcare expenditure. According to the Cancer Research UK, 371 new cases of male breast cancer were reported in 2015 in the UK.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the rising awareness regarding early symptoms of cancer and government support for healthcare facilities. According to a study published by the European Society for Medical Oncology in January 2016, there were 4.3 million new cases of cancer in China in 2015.
On the other hand, the Middle East and Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle Eastern region due to growing government initiatives for the healthcare sector.
Browse Complete 100  Pages Premium Research Report Enabled with 90 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/male-breast-cancer-market-6505

         
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Verrucous Carcinoma Market - Granular Market Report and Review, 2019

Market Scenario:
Verrucous carcinoma (VC) is a rare type of squamous cell carcinoma and is categorized under head and neck cancer.  It is mainly caused due to the chewing of tobacco or snuffing it orally. It is also called as snuff dipper's cancer. Verrucous carcinoma most commonly occurs at oral sites but is also observed in head and neck genital locations. It is mainly observed in males than in females and is found in the age group of 50 to 80 years.
The key factor responsible for influencing this market is the increasing prevalence of oral cancer. It may also be caused due to lifestyle factors such as smoking tobacco or marijuana, alcohol consumption, and others. Other key factors such as a change to sedentary lifestyle, growing consumption of alcohol, increasing tobacco users of dip, snuff, increase in smoking, rising family history of cancer prevalence, and increasing prevalence of sexually transmitted diseases by human papillomavirus are contributing towards the growth of the market. According to the World Health Organization in 2015, globally 1.1 billion people smoked tobacco. This is expected to provide favorable backgrounds for market growth during the forecast period.
However, factors such as the high cost of surgical procedures, expensive chemotherapy treatments, and side effects associated with treatments are expected to restrict the market growth during the forecast period.
Key players
Some of the key players in the global verrucous carcinoma market are Bristol-Myers Squibb Company (US) Qilu Pharmaceutical Co., Ltd. (Asia Pacific), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company. (US), F. Hoffmann-La Roche Ltd (Europe), Merck & Co., Inc. (US), Novartis AG (Europe), Pfizer Inc. (US), and others.
Segmentation
The global verrucous carcinoma market is segmented on the basis of diagnosis, treatment, and end-user. The verrucous carcinoma market, by diagnosis, is categorized into biopsy, endoscopy, and imaging tests. Imaging tests are categorized into computerized tomography scans, magnetic resonance imaging, and positron emission tomography scans. On the basis of treatment, the market is segmented into surgery, radiation therapy, chemotherapy, and targeted drug therapy. The surgery category consists of surgical excision and mohs micrographic surgery. Chemotherapy consists of bleomycin, 5-fluorouracil, cisplatin, methotrexate, and others. On the basis of end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, diagnostic centers, research centers, and others.
On the basis of region, the global verrucous carcinoma market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.
Regional Market Summary
It is estimated that North America dominated the global verrucous carcinoma market owing to the increasing innovations in clinical practice, cancer research, and access to cancer treatment in this region. The American Cancer Society in August 2018 granted USD 15,866,878 for head and neck cancer research projects. This influences the market growth in this region
Asia-Pacific was projected to be the fastest growing region for the global verrucous carcinoma market in 2017. The market is expected to witness growth owing to the rising prevalence of oral cancer, changing lifestyle, and increasing tobacco use within the population. The Center for Cancer Control and Information Services estimated 15,600 cases of oral cavity and pharynx cancer in 2017 in Japan. Such a high incidence of oral cancer favors the market growth in this region.
According to the World Health Organization’s Fact Sheet on Tobacco and Oral Health (2018), Europe has the highest prevalence of tobacco smoking among adults that is 28% of adults in Europe are engaged in tobacco smoking. Such a high prevalence of smoking in this region facilitates the market growth. Europe stood second largest in the verrucous carcinoma market owing to the increasing use of tobacco.
The Middle East and Africa holds the least share in the global verrucous carcinoma market due to the presence of poor health expenditure and economically diverse countries. However, the market is expected to witness growth due to increasing cancer care programs in the Middle East.

         
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:

Global Sacroiliitis Market Recent Trends, Growth Opportunities, Forecast by Application and Types to 2022

Market Scenario
The global sacroiliitis market is expected to witness growth during the forecast period. Sacroiliitis is a medical condition where there is inflammation in one or both sacroiliac joints situated in the pelvis and lower back. The function of a sacroiliac joint is to bear the weight of the upper body while standing, walking, and others. The condition can be diagnosed by imaging techniques. Sacroiliitis is caused due to traumatic injury, arthritis, pregnancy, infection, spondylitis, and others. The increasing prevalence of arthritis is the key factor for the market growth. According to the Centers for Disease Control and Prevention (2013to 2015), 22.7% Americans of the total population had arthritis, annually. Thus, such a high prevalence of arthritis and increasing government funding for the healthcare sector enhance the growth of this market.
However, factors such as expensive diagnostic tests and the high cost of surgical procedures are expected to restrict the market growth during the forecast period.
Segmentation
The global sacroiliitis market is segmented on the basis of diagnosis, treatment, and end-user. The sacroiliitis market, by diagnosis, is sub-segmented into imaging tests and anesthetic injections. The imaging tests category includes x-ray, MRI, and CT scan. On the basis of treatment, the market is categorized into medications, joint injections, radiofrequency denervation, electrical stimulation, joint fusion, facet block, chiropractic manipulation, and physical therapy. On the basis of end-user, the market is segmented into hospitals and clinics, pharmacies, and diagnostic centers.
On the basis of region, the global sacroiliitis market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.
The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.
Key players
Some of the key players in the global sacroiliitis market are Medacta International, SI-BONE, Globus Medical, Zyga Technology, Nutech Medical, CoorsTek Medical LLC, Aspen Medical Products, Medtronic, and others.
Regional Market Summary
The sacroiliitis market is dominated by North America owing to the high prevalence of arthritis and high healthcare investments within this region. According to the Centers for Disease Control and Prevention by 2040, 78.4 million will have doctor-diagnosed arthritis.
The rising adoption of technologically advanced systems for early diagnosis of diseases also drives the market growth in this region.
It is estimated that Europe stood second in the global sacroiliitis market. The increasing prevalence of lower back disorders and the availability of minimally invasive surgical procedures for sacroiliitis drive the market growth in this region. According to The European (2015), sacroiliac joint was the main reason for chronic low back pain in Europe.
Asia-Pacific was projected to be the fastest growing region for the global sacroiliitis market. Key factors such as the growing patient pool, the high prevalence of chronic diseases, developing healthcare infrastructure, and increasing research and development activities in the biotechnology sector influence the market in this region. The presence of major market players such as China, India, and Japan drives the market growth.
The Middle East and Africa holds the least share of the global sacroiliitis market due to the presence of stringent government policies and poor economies. However, growing awareness among the population, rising government initiatives to improve the healthcare sector, and high investments by private market players in this region can boost the market growth. 
Browse Complete 100 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/sacroiliitis-market-6290
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Posted by at No comments:
Subscribe to: Posts (Atom)